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Purpose: External beam radiotherapy (EBRT) is the gold standard adjuvant treatment after breast conserving
surgery although a recent phase 3 trial has shown the non-inferiority of intraoperative radiotherapy (IORT).
Radiation exposure of the heart and cardiac vessels causes an increase in morbidity and mortality following
EBRT for breast cancer.
We have used γ-H2AX foci formation in peripheral blood lymphocytes as a surrogate marker of dose delivered
to the heart and great vessels and have assessed the feasibility of using this technique for biological dosimetry.
Methods: 34 patients were recruited, having either EBRT or IORT as part of a randomised controlled trial (TARGIT).
Blood samples were taken prior to and after first fraction of radiotherapy, and the γ-H2AX biomarker then quantified.
Results: Data were available for 31 patients. Following TARGIT-IORT there was an increase of 0.203 foci per cell
(range −1.436 to 1.275) compared with 0.935 foci per cell (range −0.679 to 2.216) in the EBRT group; this difference
was highly significant (p = 0.009). As TARGIT-IORT treatment is completed with a single fraction, whilst EBRT requires
at least 15 fractions, the actual difference is estimated to be many times more.
Conclusions: These data show a significantly greater change in γ-H2AX foci number per cell following one fraction of
EBRT compared to TARGIT-IORT. This is the first study to demonstrate this effect using a biomarker and demonstrates a
proof of concept methodology for similar applications.
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Postoperative radiotherapy to the breast is regarded as
an essential adjunct to breast cancer conservation sur-
gery as there is overwhelming evidence that adjuvant
radiotherapy decreases the risk of local recurrence and
improves survival (Fisher et al. 1991; EBCTCG et al.
2011). However, whole breast radiotherapy is not with-
out risk or side effects. Known adverse events include
early skin erythema and desquamation as well as late
skin fibrosis and telangiectasia, acute fatigue, late lung fi-
brosis, rib fractures, secondary malignancy and ischae-
mic heart disease (START Trialists’ Group et al. 2008).* Correspondence: dwoolf@doctors.org.uk
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in any medium, provided the original work is pCardiac toxicity is the most likely of these to result in
serious morbidity as well as mortality. A recent publica-
tion on the risk of ischaemic heart disease after radio-
therapy for breast cancer (Darby et al. 2013) showed
that the overall average of the mean doses to the whole
heart was 4.9 Gy, and that the risk of a subsequent cor-
onary event increased linearly with doses at a rate of
7.4% per Gy. It also concluded that the risk increase be-
gins within a few years after exposure, and continues for
at least 20 years. Data on whole body exposure has also
shown an elevated risk of stroke and heart disease with
doses over 0.5 Gy (Shimizu et al. 2010) and the associ-
ation between breast radiotherapy and ischaemic heart
disease is widely accepted (Sardaro et al. 2012).
Modern radiotherapy techniques are safer than those
used in the past due to more accurate planning usingn Open Access article distributed under the terms of the Creative Commons
g/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction
roperly credited.
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sparing, augmented by the existence of ‘heart atlases’ to
avoid structures such as the left anterior descending cor-
onary artery (Feng et al. 2011), an area at particular risk
(Taylor et al. 2007). There are also data to show that
using hypofractionated regimes result in a lower bio-
logical dose to the heart when compared with conven-
tional schedules, due to the presumed relatively high
fraction sensitivity of the heart (Appelt et al. 2013).
Methods of reducing cardiac dose without compromis-
ing target coverage include shielding with multileaf colli-
mation or breath-hold techniques (Bartlett et al. 2013a)
but are not widely utilized (Bartlett et al. 2013b).
There has been growing interest in accelerated partial
breast irradiation (APBI) allowing treatment to be deliv-
ered safely over a shorter duration. There are several
APBI techniques available, which include linac-based
intensity-modulated radiotherapy, multicatheter intersti-
tial brachytherapy, balloon-based APBI, intra-operative
radiotherapy using a mobile linear accelerator (ELIOT)
or a miniature X-ray generator in the operating theatre
(TARGIT) (Williams et al. 2011).
With the TARGIT technology, radiation is produced
when accelerated electrons strike a gold target at the tip
of a 10-cm-long drift tube with a diameter of 3 mm,
resulting in the emission of low-energy X-rays (50 kV)
in an isotropic dose distribution around the tip (Vaidya
et al. 2001; Vaidya et al. 2002). The irradiated tissue is
kept at a fixed, known distance from the source by
spherical applicators to ensure a more uniform dose dis-
tribution. The tip of the electron drift tube sits precisely
at the epicentre of a spherical plastic applicator, the size
of which is chosen to fit the cavity after the breast can-
cer has been excised. Using this method, the walls of the
tumour cavity are irradiated to a biologically effective
dose (20 Gy to the tissue in contact with the applicator)
that rapidly attenuates over a distance of a few centime-
ters and is likely to reduce the radiation exposure to
non-breast tissue such as the cardiovascular system.
The early results of the TARGIT randomized trial indi-
cates that the single dose of radiotherapy delivered at the
time of surgery is safe and that for selected patients with
early breast cancer it can be considered as an alternative
to conventional whole breast radiotherapy (Vaidya et al.
2010). A five-year update of this trial has shown an in-
crease in local recurrence in the TARGIT group [3.3% vs
1.3%], although it was considered to be non-inferior, with
a non-significant trend towards improved overall survival
with TARGIT [HR = 0.70 (0.46-1.07)] due to fewer non-
breast cancer deaths [17 vs 35, HR 0.47 (0.26-0.84)]. There
were 2 cardiac deaths in the TARGIT group vs 8 in the
whole breast irradiation group (Vaidya et al. 2014).
Standard treatment planning systems allow the calcula-
tion of anticipated dose delivered by EBRT. A radiotherapyplanning dosimetric study (Aziz et al. 2011) has shown
that the low energy x-rays produced by IORT are likely
to reduce the radiation exposure of the cardiovascular
system compared with EBRT. However, there are cur-
rently no methods of obtaining physical dosimetry of
the heart to ascertain the dose of radiation exposure ac-
tually received after radiotherapy delivery. This study
aims to quantify the difference in exposure using a bio-
marker of radiation exposure: the phosphorylated his-
tone H2AX protein (γ-H2AX). γ-H2AX is expressed
after induction of DNA double strand breaks caused by
ionising radiation (Valdiglesias et al. 2013), created as
lymphocytes in the circulation pass through, and adja-
cent to, the irradiated field. This biomarker has been
used for the assessment of the applied intergral body
dose by radiotherapy to specific body sites (Sak et al.
2007; Sak and Stuschke 2010).
In this pilot study, we have used γ-H2AX foci forma-
tion in peripheral blood lymphocytes as a surrogate
marker of radiation dose to the heart and great vessels
with two aims: to estimate the doses of radiation actually
delivered to the heart and great vessels with TARGIT-
IORT and EBRT and to assess the feasibility of using this
technique for biological dosimetry.
Methods and materials
Subject selection and treatment
Patients selected to enter this study had a diagnosis of
early breast cancer suitable for breast conserving surgery
and requiring radiotherapy. A diagnosis of Ductal Car-
cinoma in Situ (DCIS) was permitted in the EBRT co-
hort. The majority of patients entering this study were
already enrolled in the TARGIT A study in which eli-
gible patients were randomized between standard EBRT
and IORT. Exclusion criteria included previous malig-
nancies, bilateral breast cancer, any prior exposure to
chemotherapy prior to study treatment, or exposure to
radiation in the previous 28 days (excluding EBRT plan-
ning scans). Once treatments had been allocated either
via the existing randomization structure of the TARGIT
A trial or outside of the study using routine clinical
practice, patients were approached to gain written in-
formed consent for this study. Permission for this study
was obtained from the local National Health Service Re-
search and Ethics Committee.
TARGIT-IORT was given using low energy X-rays
(50 KV), and a prescribed dose of 6 Gy at 1 cm from the
applicator surface, following a previously described tech-
nique (Vaidya et al. 2010). This corresponds to approxi-
mately 20 Gy at the applicator surface. EBRT was given
using standard 3-dimensional techniques using a dose of
40.05 Gray in 15 fractions (2.67 Gray per fraction)
(START Trialists’ Group et al. 2008). Clinicians were free
to use a boost to the tumor bed as required but this would
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not have affected the γ-H2AX analysis in this study.
Laboratory
Two 10 ml venous blood samples were obtained by the
clinical team at the time of either first fraction of EBRT or
at the time of TARGIT-IORT. The first sample was drawn
10 minutes prior to the radiation exposure to act as a base-
line measurement and a second sample was taken 20 mi-
nutes after completion of the radiation exposure.
Samples were rapidly transported to the on-site labora-
tory. Lymphocytes were isolated from 5 ml blood, with
the standard continuous gradient separation using
Isopaque-Ficoll technique. Isolated cells were placed on
covered slide chambers (Labtech, Sussex, UK). The cells
were fixed with 4% paraformaldehyde in phosphate-
buffered saline (PBS) for 10 min, blocked with methanol
and acetone respectively at 4°C, and then washed in 2 g
bovine serum albumin (BSA) in 100 ml PBS (Sigma
Aldrich, Dorset, UK). Primary antibody at dilutions of
1:300 (monoclonal, serine 139 phospho- H2AX; Millipore,
Watford, UK) was then added and incubated at 4°C over-
night. The slides were then washed with PBS/2 wt%
BSA and incubated with secondary antibody (Alexofluor
488 Goat Anti-mouse Ig G at 1:400 dilution, Invitrogen,
Paisley, UK) added for 1 h at room temperature. SlidesFigure 1 Microscopy appearance of γ-H2AX foci (nuclei appear blue,
d: EBRT post RT.were then washed in PBS/2 wt% BSA and mounted in
4′,6-diamidino-2- phenylindole. Slides were viewed with
an inverted Leica SP2 confocal laser microscope for dual
staining by sequentially scanning the two emission
channels (488 and 514 nm). For foci counting, cells were
viewed under ultraviolet illumination using a Nikon
inverted micro- scope and 3100 objective (Figure 1).
Foci were counted in at least 100 lymphocytes per slide,
with three slides counted for at each sample (prior and
after irradiation).
Statistical analysis
Foci number per cell were calculated for each sample,
and the within-patient change from baseline (pre-radio-
therapy to 20 minutes post-radiotherapy) determined by
subtraction. The mean differences of these changes be-
tween groups of women exposed to TARGIT-IORT and
EBRT radiation were compared using a two-sided two-
sample t-test. Summary statistics were calculated for the
descriptive variables. Analyses were performed using
SAS version 9.3 (SAS Institute, Cary, NC).
Results
34 patients were recruited to this study of which 20 re-
ceived EBRT and 14 received TARGIT-IORT. 3 patients
(2 EBRT and 1 TARGIT-IORT) were not evaluable duefoci appear green). a: IORT pre RT, b: IORT post RT, c: EBRT pre RT,
Table 2 Change in γ-H2AX foci number per cell
IORT EBRT
Mean 0.203 0.935
SD 0.633 0.764
n 13 18
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cessing meaning γ-H2AX foci results were unavailable.
Data are therefore reported for 31 patients. Patient
demographics and tumour characteristics are displayed
in Table 1. In the TARGIT-IORT group the median size
of the treatment applicator used was 40 mm (range 30 –
50), and the mean duration of treament was 28 minutes
(range 21–45.8).
Means and standard deviations for the change in γ-
H2AX foci number per cell for each group are sum-
marised in Table 2. Following TARGIT-IORT there was
an increase of 0.203 foci per cell (range −1.436 to 1.275;
95% CI −0.180 to 0.586) compared with an increase of
0.935 foci per cell (range −0.679 to 2.216; 95% CI 0.556 to
1.315) in the EBRT group (Figure 2); this difference was
highly significant by t-test (p = 0.009).
With TARGIT-IORT, only a single fraction of radio-
therapy is given, compared to 15 fractions of EBRT given
as a course of treatment over 3 weeks. In order to com-
pare the results of the course of radiotherapy, assuming
no boost to the tumor bed and assuming equal changes
with each fraction of EBRT (as the dose is constant), we
have multiplied the EBRT data by 15. This gives a esti-
mated change in total blood dose of γ-H2AX foci num-
ber per cell of 14.017 for EBRT compared with 0.203 for
TARGIT-IORT which is highly significant (p < 0.0001).
Discussion
In this study of patients receiving either standard external
beam radiotherapy or intra-operative radiotherapy, a bio-
marker (mean number of γ-H2AX foci per peripheral
blood lymphocyte) of DNA damage was found to be sig-
nificantly higher in the EBRT group. It has previously been
shown that there is a linear dose curve between radiation
and γ-H2AX formation and that the steepness of the
dose–response curve increased with the blood volume ofTable 1 Patient demographics and tumour characteristics
n = 31
Mean Age 64.5 years (range 41.1-94.5)
Invasive ductal carcinoma 24 (77%)
Invasive lobular carcinoma 1 (3%)
Ductal carcinoma in situ (DCIS) only 6 (20%)
Median size of tumour 18 mm (range 0.2-53.5 mm)
n = 25 (excluding DCIS)
ER +ve 23 (92%)
PR +ve 21 (84%)
HER 2 +ve 2 (8%)
Grade 1 10 (40%)
Grade 2 9 (36%)
Grade 3 6 (24%)the irradiated organ (Sak and Stuschke 2010). When these
findings are applied to our data it suggests that the higher
mean foci number are due to the larger irradiated blood
volume within the EBRT field in comparison to the
smaller TARGIT-IORT field. Part of the increase in irradi-
ated blood volume will come from the vasculature in the
breast tissue treated but it is likely that the majority of it
will be due to radiotherapy dose to the heart and great
vessels.
The clinical significance of these findings is of interest
in a number of ways. The large difference between the
increase in γ-H2AX foci number in the EBRT group and
the TARGIT-IORT group, particularly after taking into
account the 15 fractions of EBRT delivered, would sug-
gest that the cardiovascular risk induced by TARGIT-
IORT is minimal in comparison. This adds to its known
safety profile in published data (Vaidya et al. 2010) and
is in keeping with the known radiotherapy dosimetric
profile of low dose (50 Kv) x-rays.
The large difference between the EBRT and TARGIT-
IORT groups in terms of γ-H2AX foci number increase
is likely to be due to a reduced total body exposure to
radiotherapy in patients who received TARGIT-IORT, in
addition to the reduced cardiac exposure. This is of par-
ticular importance in the rare but highly clinically im-
portant question of secondary malignancies. It is well
known that high and low dose exposure to x-rays can in-
duce cancers and previous work has addressed this ques-
tion in patients receiving IORT, although using a phantom
rather than patient specific data (Aziz et al. 2011). The re-
duction in whole-body radiation from treatment with
TARGIT-IORT is likely to reduce the risk of a second can-
cer formation.
The use of biological dosimetry moves us forward
from the current use of planning algorithms, which pre-
dict doses of radiotherapy received, towards a biological
assay that shows radiation received and its effect on nor-
mal tissue in terms of double strand DNA breaks created.
It also allows dosimetry in sites that are difficult to gain
access to for physical dosimetric measurements, such as
the heart. It would also provide a suitable method for a
larger study to determine an association between radiation
dose and the risks of heart disease and stroke (Darby et al.
2013; Shimizu et al. 2010; Haque et al. 2011).
The first expert consensus statement on screening for
radiation-induced heart disease has recommended that
patients who receive external beam radiotherapy for
Figure 2 Box-and-whisker diagram of change in foci number in each of the two treatment groups.
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5 to 10 years (Lancellotti et al. 2013). This recommenda-
tion was made by the European Association of Cardio-
vascular Imaging (EACVI) of the European Society of
Cardiology and the American Society of Echocardiog-
raphy because of the increasing prevalence of radiation-
induced heart disease due to the improved rate of cancer
survival. The authors acknowledge that radiotherapy is
now given in lower doses than in the past; nevertheless,
there is still an appreciable risk of radiation-induced
heart disease, especially when the heart is in the radi-
ation field.
There are some limitations associated with this study.
Although many patients with-in this study were part of
the randomised TARGIT study, this study itself was not
randomised which may have introduced an element of
bias. DNA damage detected by this method will repair
rapidly and as such are very sensitive to any delays from
the administration of radiotherapy to the processing of
the sample. We standardised this time in the study but
some variation may still have occurred. This is especially
the case as the length of time taken to deliver the
TARGIT-IORT treatment is longer than EBRT so double
strand repair might have occurred more in the TARGIT-
IORT group. This study did not have statistical power to
detect differences between treatments to the right and
left side. Although we have hypothesised that the in-
crease in γ-H2AX foci in the EBRT group is due to the
increased volume of heart and great vessels in the field it
is possible it is in fact from the increase in whole body
dose which is difficult to account for. We hope to run a
larger study in future.
It may be hypothesised that the reduced radiotherapy
dose from TARGIT-IORT will reduce the risk of cardio-
vascular morbidity and mortality compared to EBRT.
This is the first study to demonstrate the real time effect
of radiotherapy to the heart and great vessels using a
biomarker of biological dose and demonstrates a proof
of concept methodology for similar applications.Competing interests
The authors declare that they have no competing interests.
Authors’ contribution
DW: Literature search, study design, data analysis and interpretation, writing.
NW: Literature search, study design, figures, data analysis, data interpretation,
writing. RB: Data collection, data analysis, figures, writing. YM: Data collection,
data analysis, writing. DE: Study design, data interpretation, writing. SF: Data
collection, data analysis. KP: Study design, data interpretation, writing. SS:
Study design, data interpretation, writing. MK: Study design, literature search,
data interpretation, writing. All authors read and approved the final
manuscript.
Author details
1Department of Academic Oncology, Royal Free Hospital, London, UK.
2Clinical Trials Group, University College London, London, UK. 3The Academic
Breast Unit, University College London, London, UK. 4Leeds Institute of
Cancer and Pathology, St James University Hospital, Leeds, UK.
Received: 5 June 2014 Accepted: 17 June 2014
Published: 30 June 2014
References
Appelt AL, Vogelius IR, Bentzen SM (2013) Modern hypofractionation schedules
for tangential whole breast irradiation decrease the fraction size-corrected
dose to the heart. Clin Oncol 25:147–152, doi:10.1016/j.clon.2012.07.012
Aziz MH, Schneider F, Clausen S, Blank E, Herskind C, Afzal M, Wenz F (2011) Can
the risk of secondary cancer induction after breast conserving therapy be
reduced using intraoperative radiotherapy (IORT) with low-energy x-rays?
Radiat Oncol 6:174, doi:10.1186/1748-717X-6-174
Bartlett FR, Colgan RM, Carr K, Donovan EM, McNair HA, Locke I, Evans PM,
Haviland JS, Yarnold JR, Kirby AM (2013a) The UK HeartSpare Study:
randomised evaluation of voluntary deep-inspiratory breath-hold in women
undergoing breast radiotherapy. Radiother Oncol, doi:10.1016/j.radonc.2013.04.021
Bartlett FR, Yarnold JR, Kirby AM (2013b) Clinical oncology. Clin Oncol:1–3,
doi:10.1016/j.clon.2013.08.001
Darby SC, Ewertz M, McGale P, Bennet AM, Blom-Goldman U, Brønnum D, Correa
C, Cutter D, Gagliardi G, Gigante B, Jensen M-B, Nisbet A, Peto R, Rahimi K,
Taylor C, Hall P (2013) Risk of Ischemic Heart Disease in Women after
Radiotherapy for Breast Cancer. N Engl J Med 368:987–998,
doi:10.1056/NEJMoa1209825
Early Breast Cancer Trialists’ Collaborative Group (EBCTCG), Darby S, McGale P,
Correa C, Taylor C, Arriagada R, Clarke M, Cutter D, Davies C, Ewertz M,
Godwin J, Gray R, Pierce L, Whelan T, Wang Y, Peto R (2011) Effect of
radiotherapy after breast-conserving surgery on 10-year recurrence and
15-year breast cancer death: meta-analysis of individual patient data for
10,801 women in 17 randomised trials. Lancet 378:1707–1716,
doi:10.1016/S0140-6736(11)61629-2
Feng M, Moran JM, Koelling T, Chughtai A, Chan JL, Freedman L, Hayman JA,
Jagsi R, Jolly S, Larouere J, Soriano J, Marsh R, Pierce LJ (2011) Development
and validation of a heart atlas to study cardiac exposure to radiation
Woolf et al. SpringerPlus 2014, 3:329 Page 6 of 6
http://www.springerplus.com/content/3/1/329following treatment for breast cancer. Int J Radiat Oncol Biol Phys 79:10–18,
doi:10.1016/j.ijrobp.2009.10.058
Fisher B, Anderson S, Fisher ER, Redmond C, Wickerham DL, Wolmark N,
Mamounas EP, Deutsch M, Margolese R (1991) Significance of ipsilateral
breast tumour recurrence after lumpectomy. Lancet 338:327–331
Haque R, Yood MU, Geiger AM, Kamineni A, Avila CC, Shi J, Silliman RA,
Quinn VP (2011) Long-term safety of radiotherapy and breast cancer
laterality in older survivors. Cancer Epidemiol Biomark Prev 20:2120–2126,
doi:10.1158/1055-9965.EPI-11-0348
Lancellotti P, Nkomo VT, Badano LP, Bergler J, Bogaert J, Davin L, Cosyns B,
Coucke P, Dulgheru R, Edvardsen T, Gaemperli O, Galderisi M, Griffin B,
Heidenreich PA, Nieman K, Plana JC, Port SC, Scherrer-Crosbie M, Schwartz
RG, Sebag IA, Voigt JU, Wann S, Yang PC, In collaboration with the European
Society of Cardiology Working Groups on Nuclear Cardiology and Cardiac
Computed Tomography and Cardiovascular Magnetic Resonance and the
American Society of Nuclear Cardiology, Society for Cardiovascular Magnetic
Resonan (2013) Expert consensus for multi-modality imaging evaluation of
cardiovascular complications of radiotherapy in adults: a report from the
European Association of Cardiovascular Imaging and the American
Society of Echocardiography. Eur Heart J Cardiovasc Imag 14:721–740,
doi:10.1093/ehjci/jet123
Sak A, Stuschke M (2010) Use of H2AX and other biomarkers of double-strand
breaks during radiotherapy. YSRAO 20:223–231, doi:10.1016/j.semradonc.
2010.05.004
Sak A, Grehl S, Erichsen P, Engelhard M, Grannaß A, Levegrün S, Pöttgen C,
Groneberg M, Stuschke M (2007) gamma-H2AX foci formation in peripheral
blood lymphocytes of tumor patients after local radiotherapy to different
sites of the body: dependence on the dose-distribution, irradiated site and
time from start of treatment. Int J Radiat Biol 83:639–652,
doi:10.1080/09553000701596118
Sardaro A, Petruzzelli MF, D’Errico MP, Grimaldi L, Pili G, Portaluri M (2012)
Radiotherapy and oncology. Radiother Oncol 103:133–142,
doi:10.1016/j.radonc.2012.02.008
Shimizu Y, Kodama K, Nishi N, Kasagi F, Suyama A, Soda M, Grant EJ, Sugiyama H,
Sakata R, Moriwaki H, Hayashi M, Konda M, Shore RE (2010) Radiation
exposure and circulatory disease risk: Hiroshima and Nagasaki atomic bomb
survivor data, 1950–2003. BMJ 340:b5349–b5349, doi:10.1136/bmj.b5349
START Trialists’ Group, Bentzen SM, Agrawal RK, Aird EGA, Barrett JM, Barrett-Lee
PJ, Bentzen SM, Bliss JM, Brown J, Dewar JA, Dobbs HJ, Haviland JS,
Hoskin PJ, Hopwood P, Lawton PA, Magee BJ, Mills J, Morgan DAL,
Owen JR, Simmons S, Sumo G, Sydenham MA, Venables K, Yarnold JR (2008)
The UK Standardisation of Breast Radiotherapy (START) Trial B of radiotherapy
hypofractionation for treatment of early breast cancer: a randomised trial.
Lancet 371:1098–1107, doi:10.1016/S0140-6736(08)60348-7
Taylor CW, Nisbet A, McGale P, Darby SC (2007) Cardiac exposures in breast
cancer radiotherapy: 1950s-1990s. Radiation Oncology Biology 69:1484–1495,
doi:10.1016/j.ijrobp.2007.05.034
Vaidya JS, Baum M, Tobias JS, D’Souza DP, Naidu SV, Morgan S, Metaxas M,
Harte KJ, Sliski AP, Thomson E (2001) Targeted intra-operative radiotherapy
(Targit): an innovative method of treatment for early breast cancer.
Ann Oncol 12:1075–1080
Vaidya JS, Baum M, Tobias JS, Morgan S, D’Souza D (2002) The novel technique
of delivering targeted intraoperative radiotherapy (Targit) for early breast
cancer. Eur J Surg Oncol 28:447–454, doi:10.1053/ejso.2002.1275
Vaidya JS, Joseph DJ, Tobias JS, Bulsara M, Wenz F, Saunders C, Alvarado M,
Flyger HL, Massarut S, Eiermann W, Keshtgar M, Dewar J, Kraus-Tiefenbacher
U, Sütterlin M, Esserman L, Holtveg HM, Roncadin M, Pigorsch S, Metaxas M,
Falzon M, Matthews A, Corica T, Williams NR, Baum M (2010) ArticlesTargeted
intraoperative radiotherapy versus whole breast radiotherapy for breast
cancer (TARGIT-A trial): an international, prospective, randomised,
non-inferiority phase 3 trial. Lancet 376:91–102,
doi:10.1016/S0140-6736(10)60837-9
Vaidya JS, Wenz F, Bulsara M, Tobias JS, Joseph DJ, Keshtgar M, Flyger HL,
Massarut S, Alvarado M, Saunders C, Eiermann W, Metaxas M, Sperk E,
Sütterlin M, Brown D, Esserman L, Roncadin M, Thompson A, Dewar JA,
Holtveg HMR, Pigorsch S, Falzon M, Harris E, Matthews A, Brew-Graves C,
Potyka I, Corica T, Williams NR, Baum M, TARGIT trialists’ group (2014)
Risk-adapted targeted intraoperative radiotherapy versus whole-breast
radiotherapy for breast cancer: 5-year results for local control and overall
survival from the TARGIT-a randomised trial. Lancet 383:603–613,
doi:10.1016/S0140-6736(13)61950-9Valdiglesias V, Giunta S, Fenech M, Neri M, Bonassi S (2013) H2AX as a marker of
DNA double strand breaks and genomic instability in human population
studies. Mutat Res Rev Mutat Res:1–17, doi:10.1016/j.mrrev.2013.02.001
Williams NR, Pigott KH, Keshtgar MRS (2011) Intraoperative radiotherapy in the
treatment of breast cancer: a review of the evidence. Int J Breast Cancer
2011:1–7, doi:10.1016/0167-8140(90)90163-Q
doi:10.1186/2193-1801-3-329
Cite this article as: Woolf et al.: Biological dosimetry for breast cancer
radiotherapy: a comparison of external beam and intraoperative
radiotherapy. SpringerPlus 2014 3:329.Submit your manuscript to a 
journal and beneﬁ t from:
7 Convenient online submission
7 Rigorous peer review
7 Immediate publication on acceptance
7 Open access: articles freely available online
7 High visibility within the ﬁ eld
7 Retaining the copyright to your article
    Submit your next manuscript at 7 springeropen.com
